Prof Sir Marc Feldmann, AC FAA FRS FRCP FRCPath FMedSci is a preeminent immunologist, and a Prof at the University of Oxford. After graduating with an MBBS degree from the University of Melbourne in 1967, he earned a Ph.D. in Immunology at the Walter and Eliza Hall Institute of Medical Research in 1972 with Sir Gustav Nossal. Prof Sir Marc Feldmann undertook postdoctoral research (1972) at the Imperial Cancer Research Fund’s Tumour Immunology Unit with Prof Avrion Mitchison, which led to the generation (1983) of a new hypothesis for the mechanism of autoimmunity. Testing this idea led him to leave ICRF and move to the Charing Cross Sunley Research Centre in 1985, which merged with the Kennedy Institute of Rheumatology. This then joined with the Faculty of Medicine at Imperial College in 2000. In August 2011, the Kennedy Institute of Rheumatology transferred to the University of Oxford. In 1983, he published a new hypothesis for the mechanism of induction of autoimmune diseases, highlighting the role of cytokines. Cytokines are potent signalling proteins, local hormones, which drive important processes like inflammation, immunity and cell growth. In collaboration with Ravinder N. Maini at the Kennedy Institute of Rheumatology they demonstrated that diseased joints have excessive Tumour Necrosis Factor Alpha and with the help of Dr F Brennan, TNF was defined as a therapeutic target for RA since blocking it in cultures of human arthritic joint tissue or in arthritic mice had profound beneficial effects.Prof Sir Marc Feldmann’s research has led to his recognition as a pioneer in immunology. He is Fellow of the Royal College of Physicians and of the Royal College of Pathologists.
He was elected a Fellow of multiple national Academies, the Academy of Medical Sciences and the Royal Society in London, the Australian Academy of Science, and he is a Foreign Member of the National Academy of Sciences, USA. He was knighted in the 2010 Queen’s Birthday Honour for his outstanding services to medicine. Along with Dr. Maini, Dr. Feldman was awarded the Crafoord Prize “for identification of TNF blockade as an effective therapeutic principle in rheumatoid arthritis, In 2003, the two were awarded the Albert Lasker Award for Clinical Medical Research for “discovery of anti-TNF therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases”. In 2004, the Cameron Prize for Therapeutics of University of Edinburgh. In 2007, Feldmann was awarded The European Patent Offices “European Inventor of the Year” in the Lifetime Achievement Category, the first award made in medicine. In 2008 he was awarded the Dr. Paul Janssen Award for Biomedical Research together with Maini. He was awarded the John Curtin Medal of the Australian National University in 2007. Feldmann and Maini were awarded the Ernst Schering Prize in Germany in 2010, and the Canada Gairdner International Award in 2014. Prof Sir Marc Feldmann is an Emeritus Prof at the Kennedy Institute of Rheumatology, Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences in the University of Oxford. Centocor licensed Feldmann and Maini’s key patent, and then developed Infliximab, ultimately branded as Remicade.
Remicade was the main driver of the $4.9B USD acquisition of Centocor by Johnson and Johnson and is the 4th highest selling drug in the word, reaching over $8 Billion USD in sales in 2018. Prof Sir Marc Feldmann is an expert in the development of anti-inflammatory therapeutics. Anti-TNF therapeutics which they pioneered are since 2012 the most profitable Pharmaceutical drug class with sales in 2016 that exceeded $36B USD.
Prof Sir Marc Feldmann has authored over 600 published papers reflecting an overarching commitment to both the cellular aspects of inflammatory autoimmune biology messenger molecules, cytokines and therapeutic applications.
Prof Raphael Mechoulam (Hebrew University) is the doyen of cannabis chemistry. He has isolated and synthesized these compounds for over 50 years. He was awarded an Israel Prize in Exact Sciences for his achievements in Chemistry two times. In March 2018, he was awarded an Honorary Doctorate from the University of Guelph, Ontario.
Prof Raphael Mechoulam is best known for his work in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of cannabis and for the isolation and the identification of the endogenous cannabinoids anandamide from the brain and 2-arachidonoyl glycerol (2-AG) from peripheral organs.
Additionally, he holds an Honorary Membership in the Israeli Society of Physiology and Pharmacology and has received a NIDA Discovery award in 2011. Prof Raphael Mechoulam completed his postdoctoral studies at the Rockefeller Institute after finishing his PhD at the Weizmann Institute.
Prof Raphael Mechoulam’s early achievements include the Somach Sachs Prize for ‘Best Research By a Scientist Below 35’ as well as the Kolthof Prize in Chemistry (1994). He has also received the David R. Bloom Prize for ‘excellence in pharmaceutical research’ in 1998, the Hans Medal by the Czech Chemical Society in recognition of contribution to cannabinoid chemistry in 1998, the Ariens Award by the Dutch Pharmacological Society
sponsored by Solvay Pharmaceuticals in Amsterdam and the Henrietta Szold and Henrietta Wieland prize for achievements in medical research in 2004 and 2005. Prof Raphael Mechoulam has delivered multiple honorary international lectures such as the Ulf Von Euler Lecture in Physiology at the Karolinska Institute in Stockholm.
He is also a member of the Israel Academy of Sciences and Humanities and has an honorary doctorate from Ohio State University, Complutense University and Guelph, he was also the President of the International Cannabinoid Research Society. He has been awarded multiple lifetime achievement awards and received the Rothschild Prize in 2012 for his discoveries on the influences of natural chemical substances on human behaviour. The Prime Minister of Israel awarded him the EMET prize in 2012 for his contribution to science. Furthermore, Prof Raphael Mechoulam has received the lifetime achievement award from the Eicosanoid Research Foundation as well as the Medical Faculty Prize for Excellence from Hebrew University in 2010. The Israel Chemical Society Prize for excellence in Research in 2009 was also awarded to him. Prof Raphael Mechoulam is also a consultant for the Ministry of Health in Israel, where medical marijuana is approved and regulated for around 27,000 patients.
His work in the cannabinoid field has progressed from elucidating the chemical basis of cannabis action and metabolism of cannabinoids, to identification of the endogenous ligands of a new biological system (the endocannabinoid system) and to chemical biology of the endocannabinoids and of endogenous endocannabinoid – like compounds of biological importance.
Prof Raphael Mechoulam has published over 390 scientific articles and edited 3 books related to Medical Marijuana.
Prof Richard Williams (Kennedy Institute, University of Oxford) is an expert on animal models of arthritis including pain. Richard Williams has worked at the Kennedy Institute of Rheumatology since 1989 and was a Senior Lecturer (2007-2011) and then Reader (2011-2012) at Imperial College London before joining the University of Oxford. Prof Richard Williams has numerous publications on arthritis and is an expert in his field. An example of this is Prof Richard Williams research publication, ‘Combination Cytokine Blockade: The Way Forward in Therapy for Rheumatoid Arthritis’, which was supported by the Kennedy Trust for Rheumatology Research and the European Union Seventh Frame-work programme (Project PRIAT).
He is also a Visiting Lecturer at Queen Mary University of London and the London School of Hygiene and Tropical Medicine and served for many years as an Editor of Arthritis Research and Therapy.
He has established an internationally recognised reputation in translational research and his early studies were instrumental in the development of TNF blocking biologics. He also pioneered the concept of combination therapy for rheumatoid arthritis, which has now become part of routine medical care for many patients.
He has carried out numerous projects with British and overseas industrial partners, including Merck, Pfizer, GSK, UCB, Schering, Celgene and J&J and has led an MRC DPFS project on rheumatoid arthritis.
Prof Richard Williams has over 130 publications in the medicinal spheres relating to arthritis, immunity and inflammation.
Lawrence Pemble has comprehensive experience in successfully creating, financing and developing biotechnology businesses. He has led companies and individual projects from the development and discovery phases through to financing and further clinical development.
A strong technical, entrepreneurial and corporate finance background, formatively developed within the Private Equity space where Lawrence was a Principal of a Life Science Private Equity Firm and latterly as COO of Publicly Traded and Private Biotechnology and Medical Technology companies.
Lawrence has lead numerous financing rounds, M&A activities, IPOs and has held executive roles, up to and including CEO, for start-up and private equity backed ventures, both in private and public capacities.
Lawrence has a sharp understanding and interest in the regulatory and scientific processes and procedures involved in effectively and efficiently moving young biotechnology companies from their roots to the clinical phases.
Lawrence served for over six years in the Royal Marine Commandos, leading front-line operations in Sierra Leone, Somalia, Iraq and Afghanistan. Lawrence is currently studying Executive education at the University of Oxfords’ prestigious Said Business School.
Prof Lawrence Steinman, MD. received his BA (physics) from Dartmouth in 1968 and his MD from Harvard (1973). He had a fellowship in chemical immunology at the Weizmann Institute (1974-1977) and was an intern and resident at Stanford University Medical School. Steinman served as the Chair of the Interdepartmental Program in Immunology at Stanford University from 2003-2011. He completed his Honorary PhD at the Hasselt University in 2008. Prof Lawrence Steinman currently is the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University. He is a member of the National Academy of Medicine, and the National Academy of Sciences, USA.
Prof Lawrence Steinman also founded the Steinman Laboratory in Stanford University, which is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. In this laboratory he has developed several new therapies for autoimmunity, including some in Phase 2 clinical trials in multiple sclerosis and type 1 diabetes mellitus, as well as one approved drug, natalizumab.
He has also developed microarray technology for detecting autoantibodies to myelin proteins and lipids. His laboratory team employs a diverse range of molecular and cellular approaches to devise new medications for demyelinating diseases, and to help predict which current medications will work at various stages of these diseases.
Prof Lawrence Steinman received the Frederic Sasse Award from the Free University of Berlin in 1994, the John Dystel Prize in 2004 from the National MS Society in the US, the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011 from the International Federation of MS Societies, and the Cerami Prize for Translational Research in 2015. Further achievements Prof Lawrence Steinman has been given include the Anthony Cerami Award in Translational Medicine by the Feinstein Institute of Molecular Medicine in 2015. The US congress awarded Prof Lawrence Steinman the Sen. Jacob Javits Award across 1988 and 2002.
Steinman has been involved in two prominent exits: Steinman served on the Board of Directors of Centocor which was sold to Johnson and Johnson for $4.9B USD in 1998. He founded Neurocrine Biosciences in 1992 and served on their Board of Directors. Neurocrine Biosciences (NASDAQ: NBIX) had an IPO in 1997. Neurocrine Biosciences is a San Diego, CA based biotechnology company that focuses on neurologic, psychiatric and endocrine related disorders, currently it has three late-stage clinical programs, which is a novel achievement based on Prof Steinman’s initial guidance. It currently has a market cap on the NASDAQ of $9.72B USD.
He has founded three other companies, Tolerion, Transparency Life Sciences and Atreca. Steinman heads the Scientific Advisory Board at Transparency Life Sciences. Prof Lawrence Steinman also serves on the Board of Directors at Atreca and Tolerion.
Prof Chas Bountra an expert in pharmaceutical clinical development, and pain, was previously Vice President and Head of Biology at GlaxoSmithKline for 20 years. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. More than 20 of these molecules progressed into patient studies and more than five of these delivered successful “Proof of Concept” data and progressed into late stage development. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are antiemetic in preclinical and clinical studies. He is also a Visiting Prof in Neuroscience and Mental Health at Imperial College, London. Prof Chas Bountra is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and drug discovery programmes.
Prof Chas Bountra is currently Prof of Translational Medicine at the Nuffield Department of Medicine, Head of the Structural Genomics Consortium (SGC) and an Associate Head for the Medical Sciences Division, at the University of Oxford. From October he will also be the Pro Vice Chancellor for Innovation in the University of Oxford. He has more than two decades of academic and industrial experience in target identification, lead discovery, lead optimisation, and designing phase II and III studies in several neuro-psychiatric, gastrointestinal and inflammatory conditions. He has now established the SGC as a world leading outfit for human protein structural biology and the chemical biology of epigenetics.
Prof Chas Bountra was voted one of the top innovators in the Pharmaceutical industry in 2012. Prof Chas Bountra has received multiple awards such as the Top innovator award from Pharmaphorum, the Rita and John Cornforth award from the Royal Society of Chemistry, the Best Public Private Partnership award, from Oxford Biotech Network and the Master of the Bench award from the Medicine Maker Power List in 2017. Additionally, Prof Chas Bountra was chairman in Spinifex SAB for over 7 years, which developed a novel therapeutic for pain, and was purchased by Novartis for $700M USD in June 2015.
His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, pre-competitively ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of SGC science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery.
He has received funding for multiple structural Genomics Phases from the likes of GSK, Pfizer, Lilly, Takeda, Abbvie and Merck for over $100M USD. He has given over 300 invited lectures. In 2012 he was voted one of the “top innovators in the industry”.
Prof Ruth Gallily (Hebrew University), a renowned expert on inflammation and macrophages, has evaluated Cannabinoids in vitro and in vivo models of inflammation and pain for many years.
She holds the title of Berthan and Max Densen Prof Emerita of Immunology at The Hebrew University of Jerusalem. Prof Ruth Gallily has also held visiting Profships at the Rockfeller University, The University of California at San Francisco and Los Angeles, whilst also completing research at the John Hopkins University, the Weizmann Institute and the Californian Institute of Technology. Prof Ruth Galily is a member of the American Association of Immunologists and a member of the Israel Immunology Society making her a long-standing veteran in her industry. Prof Ruth Galily has research CBD for over 20 years alongside the likes of Prof Raphael Mechoulam at the most prestigious research institutions such as the Hebrew University of Jerusalem. She spent a sabbatical year at the Kennedy Institute of Rheumatology in London with Marc Feldmann and Richard Williams, and initiated the collaborations underpinning CannBioRex.
She has numerous publications surrounding medicinal purposes of marijuana including “Pharmaceutical Compositions Comprising Cannabidiol Derivatives”, “Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice”, “Cannabidiol Lowers Incidence of Diabetes in Non-obese Diabetic Mice” and many more.
Her research interests include functions of activated macrophages: production of TNF-alpha, IL-1 and IL-6 and the generation of nitric oxide and oxygen radicals. Modulation of macrophage functions by various Agent. Cytokine production by glial cells and brain tissues. Induction and suppression of apoptosis. Effect of cannabis, cannabis derived compounds, and synthetic cannabinoids on various immune-treated parameters.
Prof Ruth Gallily has over 157 research publications in the sphere of medical.
Since 2011, Dr Fiona McCann has held group leader positions at the University of Oxford (within the Kennedy Institute of Rheumatology & Structural Genomics Consortium) and specialises in drug target discovery in inflammatory diseases and localised fibrosis.
Dr McCann has expertise in immunological sciences and her specific research interests include how cytokine receptors and epigenetic modulators can regulate disease processes to guide development of novel therapeutics.
She is an Expert in exploiting patient derived cells and tissues to build improved “near-native” assays for screening & moa studies as well as pre-clinical models for determining proof of concept towards new target discovery and translation. Dr McCann has acquired extensive project management expertise as a primary interface for a global team of study directors across academia and pharma. She is an author of over 25 scientific publications.
Dr Rajesh Munglani qualified from St George’s Hospital, University of London, in 1985. Subsequently gaining experience in A & E, paediatric medicine and eventually gaining the Fellowship of the Royal College of Anaesthetists.
He developed a strong research interest in the neurobiology of chronic pain states and also chronic spinal regional pain syndromes including reflex sympathetic dystrophies.
He was appointed John Farman Professor of The Royal College of Anaesthetists in 1996 for his contribution to pain research. He was also attached to the MRC Laboratory of Molecular Biology and also created his own molecular neurobiology laboratory with the Cambridge University Department of Medicine.
Alan Naylor is a medicinal chemist with over 30 years’ experience in Research and Development within GlaxoSmithKline.
He previously held the position of Vice President and Director of Medicinal Chemistry within the GSK Drug Discovery organization and has lead strategic, matrix and line functions involving significant international responsibilities.
He has an extensive track record of success, across a wide range of therapeutic areas, having played a major role in the discovery of over 30 development compounds, and is a co-inventor of Serevent, a major advance in the treatment of asthma.
Sallie Lamb is a Professor of Trauma Rehabilitation at the University of Oxford and the Director of the Oxford Clinical Trials Research Unit. She is also Director of the Centre for Statistics in Medicine and a Professor of Rehabilitation at the University of Warwick.
She was awarded an MSc in Rehabilitation with Distinction from Southampton University in 1991, and subsequently awarded the PPP Research Fellowship in Healthcare of Older People at the University of Oxford in 1991, where she completed a doctoral study of mobility limitation in frail older people under the supervision of eminent gerontologist, Professor Sir John Grimley Evans.
Her interests in gerontology span understanding physiological mechanisms of mobility limitation, frailty and falls in older people, to developing interventions that can be applied to improve quality of life and function of older people who have multiple co-morbidities and cognitive impairments. These include exercise interventions to target the geriatric syndromes (falls, frailty, incontinence and depression), multi-factorial interventions for the prevention of falls and fractures, minimally invasive approaches to the management of severe injury and fracture in older people, interventions for osteoarthritis, rheumatoid arthritis and back pain, and studies to improve field testing and diagnosis of gait and mobility problems in older people.
Jagdeep is a surgeon scientist and Prof at the University of Oxford, focusing on defining the molecular mechanisms of common diseases and translating his findings through to early phase clinical trials. He undertook his PhD, funded by the MRC, whilst a medical student in London. His surgical background coupled with state-of-the-art molecular biological techniques has allowed him to bring a unique insight to common, yet relatively neglected diseases and many of his findings stem from investigations in primary human tissues, rather than relying on animal models that often fail to recapitulate all the facets of the clinical condition. His research focussed on promoting tissue regeneration by targeting endogenous stem cells and reducing fibrosis.
In 2013 his group identified TNF as therapeutic target for Dupuytren’s disease, a common fibrotic condition of the hand. He recently published the data from a phase 2a clinical trial based on a novel design whereby an effective dose and preparation of anti-TNF was identified based on molecular markers of human tissue. He is now leading the phase 2b/3 trial funded by the Wellcome Trust and UK Department of Health. His work on complex fractures has led to the identification of a highly conserved physiological pathway whereby a protein released by damaged cells accelerates repair and regeneration of multiple tissues. Administration of only a single dose of the protein is effective across a range of disorders by targeting the body’s own stem cells.
Prof Laura Dugan is a neuroscientist and the director of the Geriatric Medicine Division in the Vanderbilt Brain Institute. She brings a robust research program studying the cellular mechanisms of nerves and neuronal injury in the brain, and the role of inflammation in the aging brain and in the development and progression of neurodegenerative diseases, such as Alzheimer’s. Prof Laura Dugan has completed a Fellowship at Stanford University and has previously attended the Massachusetts Institute of Technology and the Ohio State University to complete her studies in Medicine. She is an author of over 33 scientific publications.
Prof Percio Gulko served as Professor and Director of the Laboratory of Experimental Rheumatology at the Center for Genomics and Human Genetics at the Feinstein Institute for Medical Research. He was also a Professor of Molecular Medicine at Hofstra University and an Attending Physician in the Division of Rheumatology at North Shore University Hospital. Prof Gulko completed his medical degree, internship and clinical fellowship in Rheumatology at the Universidade Federal do Rio Grande do Sul. Porto Alegre in Brazil. He came to the United States as a research fellow in the Division of Rheumatology at the University of Alabama at Birmingham, and later completed his residency in Internal Medicine at the Medical College of Georgia in Augusta.
He also completed a rheumatology fellowship at the National Institutes of Health, and was a faculty member at the Divisions of Autoimmune and Molecular Disease and Rheumatology at Columbia University’s College of Physicians and Surgeons before joining the Feinstein Institute. Prof Gulko has received numerous grants from the NIH, given lectures both nationally and internationally and has been published in leading peer-reviewed journals throughout the world. He serves on the editorial board of Genes and Immunity and Physiological Genomics and is a member of the American College of Rheumatology.
Prof Irene Tracey is Head of Department for the Nuffield Department of Clinical Neurosciences and Professor of Anaesthetic Science. She graduated from the University of Oxford in Merton College with a First Class Honours, winning the Gibb’s Prize for joint top-First, and was Senior Scholar at Merton during her PhD.
Prof Tracey held a post-doctoral position at Harvard Medical School (Martinos Imaging Centre) before returning to the UK to help establish the FMRIB Centre.
In 2008, Prof Tracey was awarded the triennial Patrick Wall Medal from the Royal College of Anaesthetists and in 2009 was made a FRCA for contribution to the discipline. In addition to this, she was Deputy Chair of the UK’s Medical Research Council’s Neuroscience Mental Health Board for two years and board member from 2009-2014. Prof Tracey is an author of over 200 scientific publications.
Frank Porreca, PhD (Chair), Professor, Department of Pharmacology & Anesthesiology, College of Medicine, University of Arizona. Prof Porreca obtained his PhD degree in 1982 at Temple University, Philadelphia. After a year at Hahnemann University, he joined University of Arizona in 1985 and rose through the ranks to his present position. He received numerous awards and recognition for his research, including Founder’s Day Speaker at the University of Arizona in 2001, F.W. Kerr Award from the American Pain Society in 2000, the 9th Covino Lecturer at Harvard University in 2000, Sterling Professor Pharmacology at Albany Medical School in 2000 and the NIH MERIT Award in 2000.
In addition, he chairs and heads a number of societies and conferences and he is internationally recognized for his research in Pain. His current research interest remains in the field of pain treatment with particular interest in dynorphins, cannabinoids and bi-functional CCK-opioid ligands. He has extensive collaborations with various pharmaceutical and biotechnology companies. Prof Perreca is an author of over 25 scientific publications.
David has been a member of MNP LLP’s, a leading Canadian audit and accounting firm, management team and is responsible for providing leadership and direction to the Assurance practice across Canada. David has extensive experience in public market transactions and leverages significant expertise having served as a director on many public companies listed on the TSX, the TSX Venture, the CSE and the New York Stock Exchange.
An accounting professional since 1980, David serves as an audit partner and compliance advisor to public companies, as well as to private firms looking to become public. He brings years of experience completing significant transactions, assisting with complex accounting matters and regulatory issues, as well as with prospectus filings and other publicly filed documents.
David graduated from the University of Toronto with a Bachelor of Commerce. He is a Chartered Professional Accountant (CPA), qualifying as a Chartered Accountant (CA) in 1983.
Committed to the profession, David is a member of CPA Ontario’s Practice Inspection Committee. He is also a past member of the Ontario Securities Commission’s Small to Medium Sized Enterprise Advisory Committee and a past member of the CPA/PDAC IFRS Taskforce on Mining.
Roger Daher is a pharmacist and current owner/partner of eleven (11) pharmacies in Ontario. He has worked in the pharmacy industry for 32 years and been a licensed pharmacist for 27+ years. For the past 17 years Roger has expanded his pharmacy ownership to eleven Ontario pharmacies, ten of which are Pharmasave Pharmacies. Roger has also been a member of the Pharmasave Ontario board of directors, as well as chair of the Finance and Audit committee for the past seven years. Roger is also an Independent Director on several Boards including Fountain Asset Corp, Green space Brands and Aumento VI. All three of these companies are public trading companies on the TSXV.